Get started
Author

Shogo Matsumoto

Observed name: Matsumoto, Shogo
ORCID: 0000-0001-8599-5868
Observed ORCID: 0000-0001-8599-5868
OpenAlex ID: A5015128599
ME3183, a novel phosphodiesterase-4 inhibitor, exhibits potent anti-inflammatory effects and is well tolerated in a non-clinical study
2023 · Natsuki Kubota-Ishida, Chizuko Kaji, et al. · European Journal of Pharmacology · 9
Empirical and theoretical approaches for the prediction of human hepatic clearance using chimeric mice with humanised liver: the use of physiologically based scaling, a novel solution for potential overprediction due to coexisting mouse metabolism
2021 · Shogo Matsumoto, Hidetaka Kamimura, et al. · Xenobiotica · 4
Human total clearance values and volumes of distribution of typical human cytochrome P450 2C9/19 substrates predicted by single-species allometric scaling using pharmacokinetic data sets from common marmosets genotyped for P450 2C19
2021 · Shogo Matsumoto, Shotaro Uehara, et al. · Xenobiotica · 4
Evaluation of drug-drug interaction between nacubactam and β-lactam antibiotic (cefepime, aztreonam, meropenem, or piperacillin) in Japanese healthy participants
2026 · Jun Morita, Hiroki Sato, et al. · Antimicrobial Agents and Chemotherapy · 2
A multi-center, open-label, two-part study to investigate the effect of renal function and hemodialysis on the pharmacokinetics of the novel β-lactamase inhibitor nacubactam
2026 · Jun Morita, Kazuya Ishiwata, et al. · Antimicrobial Agents and Chemotherapy · 2
Pharmacokinetic analysis of nacubactam, a novel β-lactamase inhibitor, co-administered with meropenem in patients with a complicated urinary tract infection
2026 · Jun Morita, Kazuya Ishiwata, et al. · JAC-Antimicrobial Resistance · 2
Selection of the candidate compound at an early stage of new drug development: retrospective pharmacokinetic and metabolic evaluations of valsartan using common marmosets
2022 · Shogo Matsumoto, Shotaro Uehara, et al. · Xenobiotica · 2
Evidence of intrapulmonary penetration of nacubactam, a novel β-lactamase inhibitor, following coadministration of nacubactam with meropenem in healthy adults
2026 · Jun Morita, Kazuya Ishiwata, et al. · Antimicrobial Agents and Chemotherapy · 1
PDF
Prediction of human serum concentration–time profiles of therapeutic monoclonal antibodies using common marmosets ( Callithrix jacchus ): initial assessment with canakinumab, adalimumab, and bevacizumab
2024 · Ayaka Tajiri, Shogo Matsumoto, et al. · Xenobiotica · 1
Prediction of Human Serum Concentration–Time Profiles of Golimumab and Ustekinumab Using Pharmacokinetic Data From Common Marmosets With Assessment of Anti‐Drug Antibodies
2026 · Ayaka Tajiri, Shogo Matsumoto, et al. · Biopharmaceutics & Drug Disposition
Works count: 11
Citation count: 27
H-index: 3
I10-index:
Year
Topic
Type